篇名

過敏疾病的免疫治療

並列篇名

Immunotherapy for Allergic Diseases

DOI

10.6320/FJM.201807_22(4).0008

作者

蔡肇基(Jaw-Ji Tsai)

關鍵字

過敏疾病 ; 免疫治療 ; 過敏原 ; 過敏反應 ; allergic disease ; allergen ; allergen-based immunotherapy

出版品名稱

台灣醫學

卷期/出版年月

22卷4期

頁次

411 - 418

內容語文

繁體中文

中文摘要

免疫疾病可分為自體免疫疾病及過敏疾病,引起自體免疫疾病是因自體抗原不正常的暴露而造成,引起過敏疾病是外來過敏原過量的接觸而造成,只有過敏疾病可以用過敏原來免疫治療,過敏原造成之過敏發炎反應有很多臨床表徵和病理變化,可以依接觸的組織器官而分為鼻子過敏、支氣管過敏性氣喘、過敏性食道胃腸炎及異位性皮膚炎,也可依過敏原種類而分為食物過敏、藥物過敏、花粉過敏、塵蟎過敏等;由於過敏疾病是與過敏原的接觸有關,因此治療時還需要減少環境中之過敏原。通常過敏疾病使用藥物治療僅能緩解症狀,但對於病程改善仍然無法完全,唯有過敏免疫治療(AIT)才能改善對過敏原的耐受性,過敏原免疫治療在臨床上已超過百年,傳統上是以皮下注射為主,治療後可以改變過敏原引起之過敏反應,使病人的血清免疫及細胞免疫反應增強同時增加對過敏原耐受性並減少對新的過敏原過敏,不過過敏原注射會引起過敏反應,所以愈來愈少被使用。近年來免疫治療有許多發展及進步,例如:單株抗體dupilumab(第4介質受體抗體)已被美國FDA通過使用在異位性皮膚炎,抗IgE抗體也被使用在過敏原免疫治療之前期來預防過敏皮下注射也逐漸被其它舌下、口服及鼻内給予之方式取代。這些新的免疫治療方式必定會成為未來主要的治療方式,但確定療效及濃度還需要再深入研究,由於過敏原可以藉由分子結構的破壞來避免過敏反應,也可以藉由佐劑來修飾增強免疫反應並抑制過敏反應,因此,過敏原的結構改變處理再將疫苗給予方式改為非注射方式,這樣過敏原疫苗的免疫治療將更容易被推廣使用。

英文摘要

Immunological diseases can be divided into autoimmune diseases and allergic diseases. Autoimmune diseases are triggered by abnormal autoantigen expression and allergic diseases are triggered by the excessive environmental allergen exposure. Only allergic diseases can be treated by environmental allergen. Allergic disease can be classified by the organ of allergic inflammation after allergen exposure, ie allergic rhinitis, allergic bronchial asthma, allergic esophagitis/gastroenteritis, and atopic dermatitis. The diseases also can be classified by the exposed-allergen such as house dust mite, animal dander, pollen, food and drug allergy. The diagnosis of allergic disease is based on the allergen identification and the treatment is mainly by allergen avoidance. Since the effect of these anti-inflammatory agents can obtain only symptomatic relieve and cannot prevent the disease progression. Allergen-based immunotherapy (AIT) is the only one modality which can induce allergen tolerance and modulate the disease course and prevent disease progression. AIT has been used in practice for more than one century. The conventional AIT is given by subcutaneous injection with allergen. It can modify immediate allergic reaction induce humoral and cellular immunity to tolerate old allergen, and prevent new allergen sensitization. There are many problems of AIT not only because its safety but also its convenience. Currently allergen application has been modified through oral, sublingual, intranasal and epi-cutaneous. The allergen can also be modified by allergoid transformation and denaturation. The biologic agents dupilumab (specific monoclonal antibodies against IL4Rα(interleukin-4 receptor alpha)) had been approved for the treatment of atopic dermatitis. The other biologics, anti-IgE, can also be used to avoid allergen-induced reaction prior to AIT. Through the improvement of allergen application and modification of allergenicity, AIT can become a good alternative modality of allergy treatment in the near future.

主題分類 醫藥衛生 > 醫藥衛生綜合
參考文獻
  1. Wang IJ, Tung TH, Tang CS, et al: Allergens, air pollutants, and childhood allergic diseases. Int J Hyg Environ Health 2016;219:66-71 . doi: 10.1016/j.ijheh.2015.09.001
    連結:
  2. Hong S, Son DK, Wan R Li, et al: The Prevalence of Atopic Dermatitis, Asthma, and Allergic Rhinitis and the Comorbidity of Allergic Diseases in Children. Environ Health Toxicol 2012;27: e2012006. doi: 10.5620/eht.2012.27.e2012006
    連結:
  3. Liao EC, Chang CY, Wu CC, et al: Association of Single Nucleotide Polymorphisms in the MD- 2 Gene Promoter Region with Der p 2 Allergy. Allergy Asthma Immunol Res 2015;7:249-55. doi: 10.4168/aair.2015.7.3.249
    連結:
  4. Lipworth B, Newton J, Ram B, et al: An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med 2017;27:3. doi: 10.1038/s41533-016-0001-y
    連結:
  5. Calderón MA, Bousquet J, Canonica GW, et al: Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change? J Allergy Clin Immunol 2017;140:41-52. doi: 10.1016/j.jaci.2017.01.049
    連結:
  6. Akdis CA, Akdis M: Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med 2015;7:280ps286. doi: 10.1126/scitranslmed.aaa7390
    連結:
  7. Niu CK, Chen WY, Huang JL, et al: Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: A multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006;100:1374-83. doi: 10.1016/j.rmed.2005.11.016
    連結:
  8. Tsai JJ, Liao EC, Tsai FH, et al: The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus. J Asthma 2009;46:165-70. doi: 10.1080/02770900802553110
    連結:
  9. Yu SJ, Liao EC, Tsai JJ, et al: Effects of local nasal immunotherapy in allergic airway inflammation: Using urea denatured Dermatophagoides pteronyssinus. Hum Vaccin Immunother 2015;11:915-21. doi: 10.1080/21645515.2015.1012029
    連結:
  10. Massanari M, Nelson H, Casale T, et al: Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125:383-9. doi: 10.1016/j.jaci.2009.11.022
    連結:
  11. Blauvelt A, de Bruin-Weller M, Gooderham M, et al: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids: a 1-year, randomised, double-blinded, placebo-controlled, phase 3. Lancet 2017;389:2287-303. doi: 10.1016/S0140-6736(17)31191-1
    連結:
  12. Fajt ML, Rosenberg SL, Yecies E, et al: A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol. Allergy Asthma Proc 2017;38:309-16. doi: 10.2500/aap.2017.38.4053
    連結:
  13. Tsai JJ, Wang SR: [Appraisal of the efficacy of hyposensitization in extrinsic asthmatics]. Taiwan yi xue hui za zhi Journal of the Formosan Medical Association 1983;82:1040-4. [Article in Chinese]